SEARCH

SEARCH BY CITATION

References

  • 1
    Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA. 2009; 302: 15731579.
  • 2
    Lewiecki EM. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. J Womens Health (Larchmt). 2009; 18: 16151626.
  • 3
    Chesnut CH III, Azria M, Silverman S, Engelhardt M, Olson M, Mindeholm L. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int. 2008; 19: 479491.
  • 4
    de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006; 355: 675684.
  • 5
    MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008; 148: 197213.
  • 6
    Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. 1992; 326: 357362.
  • 7
    McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354: 821831.
  • 8
    Hattner R, Epker BN, Frost HM. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature. 1965; 206: 489490.
  • 9
    Gallagher JC, Sai AJ. Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. Maturitas. 2010; 65: 301307.
  • 10
    Reeve J. Teriparatide and Future Anabolic Treatments for Osteoporosis. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism Fifth ed. Washington, DC: American Society for Bone and Mineral Research, 2003.
  • 11
    Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med. 1990; 113: 649655.
  • 12
    Ott SM, Chesnut CH 3rd. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med. 1989; 110: 267274.
  • 13
    Papadimitropoulos E, Wells G, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev. 2002; 23: 560569.
  • 14
    O'Donnell S, Moher D, Thomas K, Hanley DA, Cranney A. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Miner Metab. 2008; 26: 531542.
  • 15
    Gallagher JC, Riggs BL, Recker RR, Goldgar D. The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proceedings of the Society for Experimental Biology & Medicine. 1989; 191: 287292.
  • 16
    Orimo H, Shiraki M, Hayashi T, Nakamura T. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3. Bone & Mineral. 1987; 3: 4752.
  • 17
    Uchiyama Y, Higuch IY, Takeda S, et al. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone. 2002; 30: 582588.
  • 18
    Erben RG, Mosekilde L, Thomsen JS, et al. Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha,25-dihydroxyvitamin D3. Journal of Bone & Mineral Research. 2002; 17: 14981511.
  • 19
    Sicinski RR, Prahl JM, Smith CM, DeLuca HF. New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J Med Chem. 1998; 41: 46624674.
  • 20
    Ke HZ, Qi H, Crawford DT, et al. A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia. J Bone Miner Res. 2005; 20: 17421755.
  • 21
    Plum LA, Fitzpatrick LA, Ma X, et al. 2MD, a new anabolic agent for osteoporosis treatment. Osteoporos Int. 2006; 17: 704715.
  • 22
    Shevde NK, Plum LA, Clagett-Dame M, Yamamoto H, Pike JW, DeLuca HF. A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation. Proc Natl Acad Sci USA. 2002; 99: 1348713491.
  • 23
    1998 Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. World Health Organization, Geneva.
  • 24
    2006 Guideline on the Evaluation of Medicinal Products in the Treatment of Primary Osteoporosis. European Medicines Agency, London.
  • 25
    1994 Guidelines for the Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis. Division of Metabolic and Endocrine Drug Products, Food and Drug Administration, Rockville, MD.
  • 26
    Parfitt AM. The cellular basis of bone remodeling: the quantum concept reexamined in light of recent advances in the cell biology of bone. Calcif Tissue Int. 1984; 36 (Suppl 1): S3745.
  • 27
    Frost HM. Bone Remodelling Dynamics. Springfield, IL: Charles C. Thomas, 1963.
  • 28
    Lelovas PP, Xanthos TT, Thoma SE, Lyritis GP, Dontas IA. The laboratory rat as an animal model for osteoporosis research. Comp Med. 2008; 58: 424430.
  • 29
    Chow JW, Badve S, Chambers TJ. A comparison of microanatomic basis for coupling between bone formation and bone resorption in man and the rat. Bone. 1993; 14: 355360.
  • 30
    Chow JW, Badve S, Chambers TJ. Bone formation is not coupled to bone resorption in a site-specific manner in adult rats. Anat Rec. 1993; 236: 366372.
  • 31
    Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003; 18: 19471954.
  • 32
    Divittorio G, Jackson KL, Chindalore VL, Welker W, Walker JB. Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis. Pharmacotherapy. 2006; 26: 104114.
  • 33
    Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res. 2000; 15: 183187.
  • 34
    Leslie WD, Metge C, Salamon EA, Yuen CK. Bone mineral density testing in healthy postmenopausal women. The role of clinical risk factor assessment in determining fracture risk. J Clin Densitom. 2002; 5: 117130.
  • 35
    Alexander JM, Bab I, Fish S, et al. Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J Bone Miner Res. 2001; 16: 16651673.
  • 36
    Wronski TJ, Yen CF, Scott KS. Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats. J Bone Miner Res. 1991; 6: 387394.
  • 37
    Black LJ, Sato M, Rowley ER, et al. et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 1994; 93: 6369.
  • 38
    Lyons RA, Johansen A, Brophy S, et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporos Int. 2007; 18: 811818.
  • 39
    Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet. 2005; 365: 16211628.
  • 40
    Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int. 2005; 76: 176186.
  • 41
    Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005; 293: 22572264.
  • 42
    2010. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 340: b5463.
  • 43
    Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2009; (2): CD000227.
  • 44
    Kubodera N. D-hormone derivatives for the treatment of osteoporosis: from alfacalcidol to eldecalcitol. Mini Rev Med Chem. 2009; 9: 14161422.
  • 45
    Matsumoto T, Miki T, Hagino H, et al. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2005; 90: 50315036.
  • 46
    Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res. 2006; 21: 292299.
  • 47
    Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008; 23: 15911600.
  • 48
    Middleton ET, Steel SA, Aye M, Doherty SM. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate. J Bone Miner Res. 2009; 25: 455462.
  • 49
    Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90: 12941301.
  • 50
    Barnes GL, Kakar S, Vora S, Morgan EF, Gerstenfeld LC, Einhorn TA. Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J Bone Joint Surg Am. 2008; 90 (Suppl 1): 120127.